{
    "root": "34012195-5fcc-eff1-e063-6294a90a98de",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "FENOFIBRATE",
    "value": "20250430",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE"
        },
        {
            "name": "VITAMIN E POLYETHYLENE GLYCOL SUCCINATE",
            "code": "O03S90U1F2"
        },
        {
            "name": "POLYOXYL 40 HYDROGENATED CASTOR OIL",
            "code": "7YC686GQ8F"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "FENOFIBRATE",
            "code": "U202363UOS"
        }
    ],
    "indications": "Fenofibrate tablets are a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: to reduce elevated LDL-C, Total-C, TG, and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia. ( 1.1 ) to treat adult patients with severe hypertriglyceridemia. ( 1.2 ) Important Limitation of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus. ( 5.1 )",
    "contraindications": "Primary hypercholesterolemia or mixed dyslipidemia: 120 mg per day. ( 2.2 ) Severe hypertriglyceridemia: 40 to 120 mg per day; the dose should be adjusted according to patient response. ( 2.3 ) Renally impaired patients: Initial dose of 40 mg per day; the dose should be increased according to the effect on renal function and lipid levels. ( 2.4 ) Geriatric patients: Select dose on the basis of renal function. ( 2.5 ) To increase absorption of fenofibrate tablets, take with food. ( 2.1 )",
    "warningsAndPrecautions": "Fenofibrate Tablets, USP are available containing 40 mg or 120 mg of fenofibrate, USP.\n                  The 40 mg tablets are white to off white, biconvex, round shaped, uncoated tablets debossed with \n  293 on one side and plain on other side. They are available as follows:\n \n                  \n                     NDC 72162-2469-9 bottles of 90 tablets\n                  \n                  \n                  \n                  \n                  \n                  The 120 mg tablets are white to off white, oval shaped, uncoated tablets debossed with \n  294 on one side and plain on other side. They are available as follows:\n \n                  \n                     NDC 72162-2470-9 bottles of 90 tablets\n                  \n                  \n                  \n                  \n                  \n                  \n                     Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]\n                  \n                  Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Keep container tightly closed.\n                  \n                  \n                  \n                  \n                  Repackaged/Relabeled by:\n  \nBryant Ranch Prepack, Inc.\n  \nBurbank, CA 91504",
    "adverseReactions": "Fenofibrate tablets are contraindicated in:\n                  \n                     patients with severe renal dysfunction, including those receiving dialysis\n  \n   [see\n   \n    Clinical Pharmacology (12.3)]\n  \n   .\n \n  \n                     patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities\n  \n   [see\n   \n    Warnings and Precautions (5.2)]\n  \n   .\n \n  \n                     patients with pre-existing gallbladder disease\n  \n   [see\n   \n    Warnings and Precautions (5.5)]\n  \n   .\n \n  \n                     patients with a known hypersensitivity to fenofibrate\n  \n   [see\n   \n    Warnings and Precautions (5.9)]\n  \n   .\n \n  \n                     nursing mothers\n  \n   [see\n   \n    Use in Specific Populations (8.2)]\n  \n   ."
}